BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 12198618)

  • 21. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients.
    Strippoli GF; Hodson EM; Jones C; Craig JC
    Transplantation; 2006 Jan; 81(2):139-45. PubMed ID: 16436954
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of sirolimus in ganciclovir-resistant cytomegalovirus infections in renal transplant recipients.
    Ozaki KS; Câmara NO; Nogueira E; Pereira MG; Granato C; Melaragno C; Camargo LF; Pacheco-Silva A
    Clin Transplant; 2007; 21(5):675-80. PubMed ID: 17845644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunohistochemically proven cytomegalovirus end-organ disease in solid organ transplant patients: clinical features and usefulness of conventional diagnostic tests.
    Fica A; Cervera C; Pérez N; Marcos MA; Ramírez J; Linares L; Soto G; Navasa M; Cofan F; Ricart MJ; Pérez-Villa F; Pumarola T; Moreno A
    Transpl Infect Dis; 2007 Sep; 9(3):203-10. PubMed ID: 17511827
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytomegalovirus UL97 mutations associated with ganciclovir resistance in immunocompromised patients from Argentina.
    Sánchez Puch S; Ochoa C; Carballal G; Zala C; Cahn P; Brunet R; Salomón H; Videla C
    J Clin Virol; 2004 Jul; 30(3):271-5. PubMed ID: 15135748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.
    Murray BM; Subramaniam S
    Transpl Infect Dis; 2004 Mar; 6(1):3-9. PubMed ID: 15225220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utility of leflunomide in the treatment of complex cytomegalovirus syndromes.
    Avery RK; Mossad SB; Poggio E; Lard M; Budev M; Bolwell B; Waldman WJ; Braun W; Mawhorter SD; Fatica R; Krishnamurthi V; Young JB; Shrestha R; Stephany B; Lurain N; Yen-Lieberman B
    Transplantation; 2010 Aug; 90(4):419-26. PubMed ID: 20683281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytomegalovirus viral load monitoring after allogeneic bone marrow transplantation in patients receiving antiviral prophylaxis.
    Howden BP; Michaelides A; Spelman DW; Spencer A; Schwarer AP; Wesselingh S; Kotsimbos TC
    Bone Marrow Transplant; 2003 Oct; 32(8):795-800. PubMed ID: 14520424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients.
    Gilbert C; Roy J; Belanger R; Delage R; Beliveau C; Demers C; Boivin G
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3669-71. PubMed ID: 11709367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human cytomegalovirus (HCMV) replication kinetics in stem cell transplant recipients following anti-HCMV therapy.
    Buyck HC; Griffiths PD; Emery VC
    J Clin Virol; 2010 Sep; 49(1):32-6. PubMed ID: 20667769
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recurrence of CMV Infection and the Effect of Prolonged Antivirals in Organ Transplant Recipients.
    Natori Y; Humar A; Husain S; Rotstein C; Renner E; Singer L; Kim SJ; Kumar D
    Transplantation; 2017 Jun; 101(6):1449-1454. PubMed ID: 27467535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Failure of pre-emptive treatment of cytomegalovirus infections and antiviral resistance in stem cell transplant recipients.
    van der Beek MT; Marijt EW; Vossen AC; van der Blij-de Brouwer CS; Wolterbeek R; Halkes CJ; Claas EC; Kroes AC
    Antivir Ther; 2012; 17(1):45-51. PubMed ID: 22267468
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Change over time in incidence of ganciclovir resistance in patients with cytomegalovirus retinitis.
    Martin BK; Ricks MO; Forman MS; Jabs DA;
    Clin Infect Dis; 2007 Apr; 44(7):1001-8. PubMed ID: 17342657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Case study: rapid emergence of a cytomegalovirus UL97 mutant in a heart-transplant recipient on pre-emptive ganciclovir therapy.
    Gilbert C; LeBlanc MH; Boivin G
    Herpes; 2001 Nov; 8(3):80-2. PubMed ID: 11867025
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resistance to combined ganciclovir and foscarnet therapy in a liver transplant recipient with possible dual-strain cytomegalovirus coinfection.
    Rodriguez J; Casper K; Smallwood G; Stieber A; Fasola C; Lehneman J; Heffron T
    Liver Transpl; 2007 Oct; 13(10):1396-400. PubMed ID: 17902124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of CMV load in solid organ transplant recipients by pp65 antigenemia and real-time quantitative DNA PCR assay: correlation with pp67 RNA detection.
    Mengoli C; Cusinato R; Biasolo MA; Cesaro S; Parolin C; Palù G
    J Med Virol; 2004 Sep; 74(1):78-84. PubMed ID: 15258972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Viral load, CMV-specific T-cell immune response and cytomegalovirus disease in solid organ transplant recipients at higher risk for cytomegalovirus infection during preemptive therapy.
    Martín-Gandul C; Pérez-Romero P; Blanco-Lobo P; Benmarzouk-Hidalgo OJ; Sánchez M; Gentil MA; Bernal C; Sobrino JM; Rodríguez-Hernández MJ; Cordero E;
    Transpl Int; 2014 Oct; 27(10):1060-8. PubMed ID: 24964364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative effects of valacyclovir on the replication of cytomegalovirus (CMV) in persons with advanced human immunodeficiency virus disease: baseline CMV load dictates time to disease and survival. The AIDS Clinical Trials Group 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group.
    Emery VC; Sabin C; Feinberg JE; Grywacz M; Knight S; Griffiths PD
    J Infect Dis; 1999 Sep; 180(3):695-701. PubMed ID: 10438356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus.
    Germi R; Mariette C; Alain S; Lupo J; Thiebaut A; Brion JP; Epaulard O; Saint Raymond C; Malvezzi P; Morand P
    Antiviral Res; 2014 Jan; 101():57-61. PubMed ID: 24184983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ganciclovir-resistant cytomegalovirus in organ transplant recipients.
    Limaye AP
    Clin Infect Dis; 2002 Oct; 35(7):866-72. PubMed ID: 12228824
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subtherapeutic ganciclovir (GCV) levels and GCV-resistant cytomegalovirus in lung transplant recipients.
    Gagermeier JP; Rusinak JD; Lurain NS; Alex CG; Dilling DF; Wigfield CH; Love RB
    Transpl Infect Dis; 2014 Dec; 16(6):941-50. PubMed ID: 25491023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.